Benchmark analyst Reuben Garner maintains Steelcase (NYSE:SCS) with a Buy and lowers the price target from $16 to $12.
Vaxart Touts Encouraging Positive Preliminary Data From Bivalent Norovirus Vaccine Study
Vaxart Inc (NASDAQ: VXRT) announced topline data from the dose-ranging Phase 2 trial of its oral pill